AFT Pharmaceuticals tracks towards NZ$300M target

• AFT Pharmaceuticals achieved sustained sales growth during the first quarter of the 2027 financial year.
• The company's share price rose to $3.04 following the market update.
• Management is driving growth through international market expansion and a pipeline of new pharmaceutical product launches.

AFT Pharmaceuticals (ASX:AFP) achieved sales growth in the first quarter of 2027 while maintaining its NZ$300 million revenue target.

This follows the 2026 financial year, where the company recorded revenue growth of 19% in Australia and 11% in New Zealand.

"We are pleased with our quarterly sales progress and the advances we have made in our R&D pipeline of, now, eight patented products that together offer the potential of significant long-term value to the business," said AFT Pharmaceuticals Managing Director Dr Hartley Atkinson.

The company also executed a pipeline option agreement targeting a market it estimates will exceed US$3 billion by 2034.

Following the announcement, the AFT Pharmaceuticals share price was up at $3.04 as of July 6’s close.

The firm has submitted 86 new product filings and is preparing to file for a further 138 products.

To support this international expansion, the company recently appointed a new senior marketing manager in the United Kingdom.